NCT07010263招募中3 期
A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112 (PD-1/VEGF Bispecific Antibody) Versus Placebo as Consolidation Treatment for Patients With Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Akeso52 个研究点 分布在 1 个国家目标入组 560 人开始时间: 2025年6月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 560
- 试验地点
- 52
- 主要终点
- Progression-Free Survival(PFS) assessed by Blinded independent center review(BIRC)
研究概览
简要总结
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria:
- •The subjects voluntarily participated in the study with full informed consent and signed written informed consent form.
- •Aged ≥18 years on day fo signing the informed consent.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Life expectancy ≥ 3 months
- •Histologically or cytologically confirmed small cell lung cancer.
- •Documented limited-stage SCLC (Stage I-III SCLC [T any, N any, M0] according to the American Joint Committee on Cancer Staging Manual [AJCC Cancer Staging Manual, 8th Edition] or the Veterans Administration Lung Study Group (VALG) stage.
- •Have Received concurrent chemoradiotherapy regimen as defined in protocol and have not progressed following concurrent chemoradiotherapy.
- •Adequate organ function.
- •Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.
排除标准
- •Histologically or cytological confirmed the presence of mixed small cell lung cancer or non-small cell lung cancer components.
- •Toxicities from previous anti-tumor treatments have not resolved to grade 0 or 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or to the levels specified in inclusion/exclusion criteria, except for alopecia.
- •Symptoms or signs of primary disease deterioration that the investigator judges clinically unacceptable, such as cachexia.
- •Presence of pleural effusion, pericardial effusion, or ascites, which was clinically symptomatic or requiring frequent drainage.
- •History of active malignant tumors within the previous 5 years.
- •Received major surgery within 28 days prior to the first dose of study drug, or expected to undergo major surgery during the study period within 28 days after the first dose of study drug.
- •Uncontrolled comorbidities, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, and other related diseases..
- •Have serious neurological or mental illnesses, including dementia and epileptic seizures.
- •Pregnant or lactating women.
- •Have cardiovascular or cerebrovascular diseases or risk factors.
- •Prior treatments with systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration of the study drugs. Prior treatment with Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications within 1 weeks before the first administration of the study drugs.
- •Prior treatments targeting immune mechanisms, including, but not limited to, immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy.
- •Prior treatments with anti-angiogenic therapy.
- •Subjects requiring systemic treatment with corticosteroids (>10mg/day prednisone or equivalent dose) or other immunosuppressive drugs within 14 days prior to the first dose of study drug.
- •Known history of severe hypersensitivity reactions to other monoclonal antibodies or with a known history of allergy or hypersensitivity reactions to any of study drugs or their components.
- •Active autoimmune diseases that require systemic treatment within 2 years prior to the study, or autoimmune diseases that the investigator judges to be potentially recurrent or require planned treatment.
- •Known interstitial lung disease or non infectious pneumonia, which currently has symptoms or requires systemic corticosteroid treatment in the past,or investigator juges may affect the toxicity assessment or management related to the study treatment.
- •Known severe infection within 4 weeks prior to the first dose of study drug. Known active tuberculosis. Known active syphilis infection. Known history of immunodeficiency or positive HIV test results.
- •.Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- •Active hepatitis B or active hepatitis C.
- •Received a live vaccine within 30 days prior to the first dose of study drug, or planning to receive a live vaccine during the study period.
研究组 & 干预措施
Ak112 arm
Experimental
AK112 intravenous [IV]),every 3 weeks
干预措施: AK112 (Drug)
Placebo arm
Placebo Comparator
Placebo intravenous [IV]),every 3 weeks
干预措施: Placebo (Other)
结局指标
主要结局
Progression-Free Survival(PFS) assessed by Blinded independent center review(BIRC)
时间窗: Approximately 6 years
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1
Overall Survival (OS)
时间窗: Approximately 6 years
OS is defined as the time from randomization or first dosing to death due to any cause.
次要结局
- Number of participants with adverse event (AE)(Approximately 6 years)
- PFS assessed by investigator per RECIST v1.1(Approximately 6 years)
- Objective Response Rate (ORR) assessed by BICR Per RECIST v1.1(Approximately 6 years)
- ORR assessed by investigator Per RECIST v1.1(Approximately 6 years)
- Disease control rate(DCR) assessed by BICR per RECIST v1.1(Approximately 6 years)
- DCR assessed by investigator per RECIST v1.1(Approximately 6 years)
- Duration of Response (DOR) assessed by BICR per RECIST v1.1(Approximately 6 years)
- DOR assessed by investigator per RECIST v1.1(Approximately 6 years)
研究者
研究点 (52)
Loading locations...
相似试验
招募中
3 期
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06022861Shandong Boan Biotechnology Co., Ltd510
已完成
3 期
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast CancerHER2-positive Breast CancerNCT03588091Jiangsu HengRui Medicine Co., Ltd.355
进行中（未招募）
3 期
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)Chronic Kidney Disease With High ProteinuriaNCT06087835AstraZeneca1,835
尚未招募
3 期
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 InhibitorsNCT06929325CSPC ZhongQi Pharmaceutical Technology Co., Ltd.312
已完成
3 期
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )Esophageal Squamous Cell CarcinomaNCT03748134Innovent Biologics (Suzhou) Co. Ltd.746